BTIG Reiterates Buy on NRX Pharmaceuticals, Maintains $25 Price Target
Benzinga Newsdesk 8 months ago
NewsPrice TargetReiterationAnalyst Ratings
BTIG analyst Thomas Shrader reiterates NRX Pharmaceuticals (NASDAQ:NRXP) with a Buy and maintains $25 price target.
BTIG analyst Thomas Shrader reiterates NRX Pharmaceuticals (NASDAQ:NRXP) with a Buy and maintains $25 price target.